July 11, 2024
Reprocell Inc.
JTB Corp.

Reprocell and JTB commence offering
Regenerative Medicine Grade iPS Exosomes
Reprocell Inc. (Headquarters: Kanagawa, hereinafter "Reprocell") and JTB Corp.
(Headquarters: Tokyo, hereinafter "JTB") announce that JTB becomes the general agent
for handling regenerative medicine grade*1 iPS exosomes (autologous*2, allogeneic*3)(hereinafter "iPS exosomes") manufactured by Reprocell, and commences selling iPS
exosomes to medical institutions and clinics through the Japan Health & ResearchInstitute (Headquarters: Tokyo, hereinafter "Japan Health & Research Institute").
*Reprocell and JTB have been in a business partnership since October 2022.
https://www.jtbcorp.jp/jp/newsroom/2022/10/jtb-personal-ips.html

Image-1

(3)

(1)
(1)
(2)
(3)
(4)
(5)

Nucleus
Cell
Extracellular vesicle
ExosomeSupernatant collection

(2)

(5)

(4)

＜Exosomes are extracellular vesicles produced by cells that range from 50-150nm in size.

■Background and History
Exosomes are granular substances with a diameter of 50-150 nm (nanometers: one
billionth of a meter) secreted by cells, playing a role in intercellular communication
within the body. Currently, exosomes secreted from stem cells derived from fat,umbilical cord, and dental pulp (hereinafter "stem cell exosomes") are widely distributedfor cosmetic purposes.
Reprocell and JTB have agreed to expand Japan-domestic and global sales of iPS
exosomes. The global market size of exosomes is reaching 213 million USD in 2022 and
it is estimated to 1,807 million USD in 2033, with the compound annual growth rate of30%.
Citation：SDKI Analytics(https://www.sdki.jp/reports/exosome-research-products-market/106511)●Regarding iPS exosomes(autologous & allogeneic)
JTB will provide iPS exosomes that produced by Reprocell to medical institutions andclinics. Fundamental research and animal experiment results on iPS exosomes have beenreported overseas.

●Manufacturing Method and Safety
Reprocell produces a next-generation reprogramming method (mRNA method*4) without
viruses and genetic introduction to create iPS cells, thus eliminating the risk of foreign
factors. The cells utilized in the production of iPS exosomes are tested for viruses andbacteria to meet the regulations of regenerative medicine in Japan, the US, and Europe.
The production process takes place in facilities licensed to manufacture specific cellprocessed products. Furthermore, repeated purification and concentration processes
thoroughly eliminate impurities, achieving high-purity regenerative medicine grade iPS
exosomes.
■OverviewTo promote iPS exosomes as a Japanese technology domestically and globally, and toestablish a distribution system to Japanese medical institutions and clinics, the handlingof 'Personal iPS*5' has been supervised by Dr. Toshio Miyata (Chairman of the MedicalCorporation DEN). Test operations will commence at Mii Clinic Yoyogi (Tokyo), Shiba
International Clinic (Tokyo), HAAB BEAUTY CLINIC Minami Aoyama Main Branch (Tokyo),my place beauty clinic (Osaka), and Mii Clinic Minoo (Osaka). At the same time, throughJTB's patient collection and referral scheme, we aim to further expand medical inboundby selling the iPS exosome plans provided by medical institutions and clinics to foreign
visitors to Japan.
＜Main Roles of Cooperation＞
・Reprocell: Manufacturing iPS exosomes
・JTB: Promotion of domestic and overseas sales of iPS exosomes
・Japan Health & Research Institute: Reception and counter services for handling stores(medical institutions and clinics)＜Cooperation Scheme＞
Image-2

<Company Information>■Reprocell Inc. (https://reprocell.co.jp/)
Reprocell (TSE Growth: 4978) was established in 2003 as a biotech venture originatingfrom Kyoto University and the University of Tokyo. With the world's most advanced iPS
cell technology, the company's products and services are widely used in universities andpharmaceutical companies worldwide. Reprocell is also actively engaged in thedevelopment of regenerative medical products and is a leading company in the iPS cellfield.
■JTB Corp. (https://www.jtbcorp.jp/jp/)
JTB aims to connect people, places, and things to create new value and foster innovation
in local communities through its "Bringing People, Places and Possibilities Together"*6Since 2008, JTB has been engaged in medical coordination business in medical inboundtourism to Japan.
■Japan Health & Research Institute (https://www.jph-ri.or.jp/index.html)
The Japan Health & Research Institute is dedicated to promoting health and recovery forthe public through natural environment-based health promotion programs such as spa
therapy and climate therapy, operating comprehensive health check-up centers, andadvancing preventive medicine.
*1 Regenerative medicine grade: Grade based on standards for cell processing for clinical use(infection testing of cells and manufacturing facility).
*2 Regenerative medicine-grade iPS exosomes (autologous): iPS exosomes manufactured from thepatient's own cells (iPS cells)*Autologous: Manufactured from the patient’s own iPS cells, requiring an application for
Reprocell’s Personal iPS service, which provides manufacturing and storage of individual iPS cells.
* ３ Regenerative medicine-grade iPS exosomes (allogeneic): iPS exosomes manufactured fromanother person's cells (iPS cells)*4 mRNA method: A method for producing iPS cells using messenger RNA (ribonucleic acid).
*5 Personal iPS: A completely new personal cell storage service utilizing technology to create iPS
cells from urine or teeth. By storing one's own iPS cells, it prepares for future regenerative medicine
applications, such as cell transplants without rejection reactions.
* "Personal iPS" is a registered trademark of Reprocell Co., Ltd.
*6”Bringing People, Places and Possibilities Together”is a registered trademark of JTB Corporation.

―――――――――――――――――――――――――――――――――――――――――――――――――
Contact Information⚫

For inquiries regarding iPS exosomes: Reprocell Inc.

⚫

For inquiries regarding the handling of iPS exosomes for medical institutions andclinics: Japan Health & Research Instituteinfo_jp@reprocell.com

ips-exo@jph-ri.or.jp

Website for prospective iPS exosome dealers:
https://www.jph-ri.or.jp/medical/ips.html⚫

For inquiries from the press: JTB Corp. Branding, Marketing & Communications Team
TEL: +81-(0)3-5796-5833(Tokyo) ／+81-(0)6-6260-5108（Osaka）